APEX1 ELISA Kit

Name: APEX1 ELISA Kit
SKU: DEIA-XYA223
Rating: 5 (1 reviews)

Regulatory status: For research use only, not for use in diagnostic procedures.

COA

SDS

Datasheet

Summary

Sample

cultured cells

Species Reactivity

Human; Mouse; Rat

Detection Method

Indirect ELISA

Intended Use

The APEX1 Cell-Based ELISA Kit is a convenient, lysate-free, high throughput and sensitive assay kit that can monitor APEX1 protein expression profile in cells. The kit can be used for measuring the relative amounts of APEX1 in cultured cells as well as screening for the effects that various treatments, inhibitors (ie. siRNA or chemicals), or activators have on APEX1.

Contents of Kit

1. 96-Well Cell Culture Clear-Bottom Microplate: 1 plate
2. 10x TBS: 24 mL (10x), Clear
3. Quenching Buffer: 24 mL (1x), Clear
4. Blocking Buffer: 50 mL (1x), Clear
5. 10x Wash Buffer: 50 mL (10x), Clear
6. 100x Anti-APEX1 Antibody (Rabbit Polyclonal): 60 μL (100x), Purple
7. 100x Anti-GAPDH Antibody (Mouse Monoclonal): 60 μL (100x), Green
8. HRP-Conjugated Anti-Rabbit IgG Antibody: 6 mL (1x), Glass
9. HRP-Conjugated Anti-Mouse IgG Antibody: 6 mL (1x), Glass
10. Primary Antibody Diluent: 12 mL (1x), Clear
11. Ready-to-Use Substrate: 12 mL (1x), Brown
12. Stop Solution: 12 mL (1x), Clear
13. Crystal Violet Solution: 6 mL (1x), Glass
14. SDS Solution: 24 mL (1x), Clear
15. Adhesive Plate Seals: 4 seals

Storage

4°C/6 Months

Citations

Have you cited DEIA-XYA223 in a publication? Let us know and earn a reward for your research.

Documents

pdf COA

pdf SDS

pdf Datasheet

QA & Reviews

Customer Reviews

References

Structural insights into the ligand-binding hot spots of APEX1: an in silico analysis

MEDICINAL CHEMISTRY RESEARCH

Authors: Balasubramanian, Pavithra K.; Balupuri, Anand; Cho, Seung Joo

Abstract

Human apurinic/apyrimidinic endonuclease (APEX1) is a multifunctional protein involved in the repair of DNA damage. It plays a vital role in the base excision repair. Overexpression of APEX1 is observed in a variety of cancers. High APEX1 expression has been associated with deprived result to radio and chemotherapy. It also plays an important role in therapeutic agent resistance and disease suppression. If APEX1 activities could be regulated, the protein would be a favorable and efficient cancer target. So far, inhibitor binding site of APEX1 is not studied in detail. The present study focuses on the identification of ligand-binding hot spot residues of APEX1. Docking studies were performed on seventy-one recently reported APEX1 inhibitors. The docking results identified that most of the compounds with biphenyl moiety occupied the same binding site. Majority of compounds were found to form hydrogen bond interaction with Asn174, Arg156, His309, Tyr128, Asn212, Arg181 and Asn226 and hydrophobic interaction with Phe266, Trp280 and Tyr128. The results could provide useful structural insights about the binding mode of APEX1 inhibitors and the crucial hot spot residues which are essential for ligand recognition.

Association of polymorphisms in base excision repair genes with the risk of breast cancer: A case-control study in north Indian women

ONCOLOGY RESEARCH

Authors: Mitra, Amit Kumar; Singh, Neetu; Singh, Ashok; Garg, Vivek Kumar; Agarwal, Amit; Sharma, Mandira; Chaturvedi, Rashmi; Rath, Srikanta Kumar

Abstract

Inheritance of common genetic variants at one or more base excision repair (BER) genes may result in a reduced DNA repair capacity and in an increased risk of cancers like breast cancer. The present case-control study with 390 north Indian women (155 breast cancer cases and 235 controls) was aimed to investigate the association of seven nonsynonymous BER gene polymorphisms viz. rs1130409/T1865G (APEX1), rs1799782/T22142C (XRCC1), rs25487/G23990A (XRCC1), rs4989588/T3337A (FEN1), rs4989586/G3259A (FEN1), rs4989587/C3315T (FEN1), and rs1050525/G6941T (PCNA) with breast cancer susceptibility. Statistically significant association with breast cancer risk was observed for rs1130409 homozygous mutant GG [odds ratio (OR) 3.35, 95% confidence interval (CI) 1.36-8.26), heterozygous GT (OR 2.42, 95% Cl 1.56-3.76), and combined mutant (GT + GG) (OR 2.52, 95% CI 1.65-3.86] genotypes and rs25487 homozygous mutant AA (OR 2.91, 95% CI 1.66-5.10) and combined mutant (AA + AG) (OR 1.41, 95% CI 0.903-2.19) genotypes, whereas protective association was exhibited by rs1799782 homozygous mutant CC (OR 0.413, 95% CI 0.082-2.08), heterozygous TC (OR 0.351, 95% CI 0.189-0.650), and combined mutant (TC + CC) (OR 0.357, 95% CI 0.199-0.641) genotypes. Association study using reconstructed haplo-types of XRCC1 gene showed positive association for the TA haplotype (OR 2.014, 95% CI 1.462-2.775) and a protective association for the CG haplotype (OR 0.173, 95% CI 0.052-0.576) pertaining to breast cancer risk. The results indicate that the polymorphisms rs1130409 (APEX1) and rs25487 (XRCC1) might be involved in contributing towards breast cancer susceptibility, while rs1799782 (XRCC1) might have protective influence.